Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

ARTICLE | Product Development

Pharmas challenging Novo and Lilly in obesity

An analysis of which major pharmas are in, out, or still deciding whether to take on obesity heavyweights Eli Lilly and Novo Nordisk

By Stephen Hansen, Director of Biopharma Intelligence

November 15, 2024 10:20 PM UTC

Editor in Chief Simone Fishburn selected this story as one of BioCentury's Best of 2024. To see the full list, click here.

Eli Lilly and Novo Nordisk have clearly set themselves apart from other pharmas in the scale of their pipelines, revenues and business development activities in obesity. But with what is projected to be the largest-ever market opportunity, other pharmas aren’t sitting this one out. Or are they? ...

Get Unlimited Access

To view this item, login or register for a free account.

Start a Free Trial Log In

Or Purchase This Article

BCIQ Company Profiles

Amgen Inc.

Boehringer Ingelheim GmbH